Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published January 15, 2002 Previous issue | Next issue

  • Volume 109, Issue 2
Go to section:
  • In this issue
  • Letter to the Editor
  • Perspectives
  • Commentaries
  • Research Articles
In this issue
In This Issue
John Ashkenas
John Ashkenas
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):153-153. https://doi.org/10.1172/JCI119942.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

John Ashkenas

×
Letter to the Editor
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis
Marzia Pennati, … , Maria Grazia Daidone, Nadia Zaffaroni
Marzia Pennati, … , Maria Grazia Daidone, Nadia Zaffaroni
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):285-286. https://doi.org/10.1172/JCI14891.
View: Text | PDF

Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis

  • Text
  • PDF
Abstract

Authors

Marzia Pennati, Gennaro Colella, Marco Folini, Lorenzo Citti, Maria Grazia Daidone, Nadia Zaffaroni

×
Perspectives
Membrane domains and the immunological synapse: keeping T cells resting and ready
Michael L. Dustin
Michael L. Dustin
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):155-160. https://doi.org/10.1172/JCI14842.
View: Text | PDF

Membrane domains and the immunological synapse: keeping T cells resting and ready

  • Text
  • PDF
Abstract

Authors

Michael L. Dustin

×

ITAMs versus ITIMs: striking a balance during cell regulation
Daniel D. Billadeau, Paul J. Leibson
Daniel D. Billadeau, Paul J. Leibson
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):161-168. https://doi.org/10.1172/JCI14843.
View: Text | PDF

ITAMs versus ITIMs: striking a balance during cell regulation

  • Text
  • PDF
Abstract

Authors

Daniel D. Billadeau, Paul J. Leibson

×
Commentaries
Clearing the way to implantation
Eli Y. Adashi, Minoru Fukuda
Eli Y. Adashi, Minoru Fukuda
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):169-170. https://doi.org/10.1172/JCI14865.
View: Text | PDF

Clearing the way to implantation

  • Text
  • PDF
Abstract

Authors

Eli Y. Adashi, Minoru Fukuda

×

CD40L in autoimmunity and mucosally induced tolerance
Mi-Na Kweon, Hiroshi Kiyono
Mi-Na Kweon, Hiroshi Kiyono
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):171-173. https://doi.org/10.1172/JCI14930.
View: Text | PDF

CD40L in autoimmunity and mucosally induced tolerance

  • Text
  • PDF
Abstract

Authors

Mi-Na Kweon, Hiroshi Kiyono

×
Research Articles
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands
Hubert C. Chen, … , Peter M. Elias, Robert V. Farese Jr.
Hubert C. Chen, … , Peter M. Elias, Robert V. Farese Jr.
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):175-181. https://doi.org/10.1172/JCI13880.
View: Text | PDF

Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands

  • Text
  • PDF
Abstract

Acyl CoA:diacylglycerol acyltransferase (DGAT) is a ubiquitously expressed enzyme that catalyzes the final reaction in the major pathways of triglyceride synthesis. Mice lacking DGAT1 (Dgat–/–) demonstrate significant changes in lipid metabolism in several tissues, including the skin. Here we report the effects of DGAT1 deficiency on fur and sebaceous glands. Adult Dgat–/– mice had dry fur and hair loss, which were associated with atrophic sebaceous glands and fur lipid abnormalities. As a result, Dgat–/– mice had impaired water repulsion and defective thermoregulation after water immersion. These phenotypes were mostly absent in Dgat–/– mice with leptin deficiency, indicating an unexpected role for leptin in modulating the skin phenotype. Our findings indicate that DGAT1 plays an important role in normal fur and sebaceous gland physiology and provide evidence that leptin modulates these processes in the skin.

Authors

Hubert C. Chen, Steven J. Smith, Bryan Tow, Peter M. Elias, Robert V. Farese Jr.

×

β2 integrins are required for skin homing of primed T cells but not for priming naive T cells
Stephan Grabbe, … , Cord Sunderkötter, Karin Scharffetter-Kochanek
Stephan Grabbe, … , Cord Sunderkötter, Karin Scharffetter-Kochanek
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):183-192. https://doi.org/10.1172/JCI11703.
View: Text | PDF

β2 integrins are required for skin homing of primed T cells but not for priming naive T cells

  • Text
  • PDF
Abstract

β2 integrins are of critical importance for leukocyte extravasation through vascular endothelia and for T cell activation. To elucidate the role of β2 integrins in T cell–mediated immune responses, allergic contact dermatitis (ACD), irritant dermatitis, and delayed-type hypersensitivity (DTH) were assessed in mice lacking the β2 integrin subunit, CD18. ACD and DTH responses, but not edema formation, were severely suppressed in CD18–/– mice. Extravasation of CD18–/– T cells into eczematous skin lesions was greatly impaired, whereas migration of Langerhans cell precursors and dendritic cells was normal in CD18–/– mice. CD18–/–lymph nodes (LNs) contained an abnormal population of CD3–CD44high lymphocytes and showed evidence of widespread T cell activation. T cells from regional LNs of sensitized CD18–/– mice proliferated in response to hapten challenge, and subcutaneous injection of sensitized syngeneic LN cells directly into ears of hapten-challenged naive recipients restored the defective ACD in CD18–/– mice, suggesting that CD18 is not required for priming of naive T cells but is indispensable for T cell extravasation. Thus, a dysfunction of T cells, in addition to granulocytes, may contribute to the pathophysiology of leukocyte adhesion deficiency type I, which arises from mutations in the human CD18 gene.

Authors

Stephan Grabbe, Georg Varga, Stefan Beissert, Meike Steinert, Gunther Pendl, Stephan Seeliger, Wilhelm Bloch, Thorsten Peters, Thomas Schwarz, Cord Sunderkötter, Karin Scharffetter-Kochanek

×

TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury
James J. Farrell, … , Daniel K. Podolsky, Timothy C. Wang
James J. Farrell, … , Daniel K. Podolsky, Timothy C. Wang
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):193-204. https://doi.org/10.1172/JCI12529.
View: Text | PDF

TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury

  • Text
  • PDF
Abstract

Trefoil factor family 2 (TFF2), also known as spasmolytic polypeptide, is a member of the trefoil family of peptides and is expressed primarily in the mucous neck cells of the gastric mucosa. To study the physiologic role of TFF2, we have generated TFF2-deficient mice through targeted gene disruption. Homozygous mutant mice were viable and fertile without obvious gastrointestinal abnormalities. However, quantitative measurements revealed a significant decrease in gastric mucosal thickness and in gastric mucosal proliferation rates. In addition, there was a twofold increase in activated parietal cells resulting in a twofold increase in basal and stimulated gastric acid output and an undetectable serum gastrin level. The TFF2-deficient mice also showed a significant increase in the degree of gastric ulceration after administration of indomethacin. Taken together, these results suggest a physiologic role for TFF2 to promote mucosal healing through the stimulation of proliferation and downregulation of gastric acid secretion.

Authors

James J. Farrell, Douglas Taupin, Theodore J. Koh, Duan Chen, Chun-Mei Zhao, Daniel K. Podolsky, Timothy C. Wang

×

Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent
Kristen V. Khanna, … , Leonard Shultz, Richard B. Markham
Kristen V. Khanna, … , Leonard Shultz, Richard B. Markham
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):205-211. https://doi.org/10.1172/JCI13236.
View: Text | PDF

Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent

  • Text
  • PDF
Abstract

Because both HIV-1 virions and HIV-infected cells are present in the semen and cervical mucus of infected individuals, HIV-1 prevention strategies must consider both cell-free and cell-associated virus. Antibodies that target HIV-1 virions have been shown to prevent vaginal transmission of cell-free virus in macaques, but since cell-associated transmission has not been reliably demonstrated in this model system, no strategies to prevent such transmission have been tested. We have employed a mouse model in which SCID mice carry human peripheral blood leukocytes (HuPBLs). In these mice, vaginal transmission of cell-associated, but not cell-free, HIV-1 transmission occurs, mediated by transepithelial migration of HIV-infected cells. Topical application of β-cyclodextrin (β-CD), a cholesterol-sequestering agent that interferes with cell migration and budding of virus from lipid rafts, blocks transmission of cell-associated HIV-1. The HuPBL-SCID model of vaginal HIV-1 transmission should prove useful for investigating cell-associated HIV-1 transmucosal HIV-1 transmission, as well as for screening reagents for their potential efficacy in preventing sexual HIV-1 transmission.

Authors

Kristen V. Khanna, Kevin J. Whaley, Larry Zeitlin, Thomas R. Moench, Karim Mehrazar, Richard A. Cone, Zhaohao Liao, James E.K. Hildreth, Timothy E. Hoen, Leonard Shultz, Richard B. Markham

×

Heparin cofactor II inhibits arterial thrombosis after endothelial injury
Li He, … , Daniel T. Eitzman, Douglas M. Tollefsen
Li He, … , Daniel T. Eitzman, Douglas M. Tollefsen
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):213-219. https://doi.org/10.1172/JCI13432.
View: Text | PDF

Heparin cofactor II inhibits arterial thrombosis after endothelial injury

  • Text
  • PDF
Abstract

Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin rapidly in the presence of dermatan sulfate, heparan sulfate, or heparin. HCII has been proposed to regulate coagulation or to participate in processes such as inflammation, atherosclerosis, and wound repair. To investigate the physiologic function of HCII, about 2 kb of the mouse HCII gene, encoding the N-terminal half of the protein, was deleted by homologous recombination in embryonic stem cells. Crosses of F1HCII+/– animals produced HCII–/– offspring at the expected mendelian frequency. Biochemical assays confirmed the absence of dermatan sulfate–dependent thrombin inhibition in the plasma of HCII–/– animals. Crosses of HCII–/– animals produced litters similar in size to those obtained from heterozygous matings. At 1 year of age, HCII-deficient animals were grossly indistinguishable from their wild-type littermates in weight and survival, and they did not appear to have spontaneous thrombosis or other morphologic abnormalities. In comparison with wild-type animals, however, they demonstrated a significantly shorter time to thrombotic occlusion of the carotid artery after photochemically induced endothelial cell injury. This abnormality was corrected by infusion of purified HCII but not ovalbumin. These observations suggest that HCII might inhibit thrombosis in the arterial circulation.

Authors

Li He, Cristina P. Vicente, Randal J. Westrick, Daniel T. Eitzman, Douglas M. Tollefsen

×

Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection
Xiping Zhao, … , Hubert E. Blum, Thomas F. Baumert
Xiping Zhao, … , Hubert E. Blum, Thomas F. Baumert
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):221-232. https://doi.org/10.1172/JCI13011.
View: Text | PDF

Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection

  • Text
  • PDF
Abstract

Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide, but the study of HCV infection has been hampered by the lack of an in vitro or in vivo small animal model. The tree shrew Tupaia belangeri is susceptible to infection with a variety of human viruses in vivo, including hepatitis viruses. We show that primary Tupaia hepatocytes can be infected with serum- or plasma-derived HCV from infected humans, as measured by de novo synthesis of HCV RNA, analysis of viral quasispecies evolution, and detection of viral proteins. Production of infectious virus could be demonstrated by passage to naive hepatocytes. To assess whether viral entry in Tupaia hepatocytes was dependent on the recently isolated HCV E2 binding protein CD81, we identified and characterized Tupaia CD81. Sequence analysis of cloned Tupaia cDNA revealed a high degree of homology between Tupaia and human CD81 large extracellular loops (LEL). Cellular binding of E2 and HCV infection could not be inhibited by anti-CD81 antibodies or soluble CD81-LEL, suggesting that viral entry can occur through receptors other than CD81. Thus, primary Tupaia hepatocytes provide a potential model for the study of HCV infection of hepatocytes.

Authors

Xiping Zhao, Zhen-Ya Tang, Bettina Klumpp, Guido Wolff-Vorbeck, Heidi Barth, Shoshana Levy, Fritz von Weizsäcker, Hubert E. Blum, Thomas F. Baumert

×

Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis
Laurence M. Howard, … , Mauro C. Dal Canto, Stephen D. Miller
Laurence M. Howard, … , Mauro C. Dal Canto, Stephen D. Miller
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):233-241. https://doi.org/10.1172/JCI14374.
View: Text | PDF

Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis

  • Text
  • PDF
Abstract

Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated demyelinating disease of the CNS with similarities to multiple sclerosis. We and others have shown that a short-term course of anti-CD154 mAb treatment to block CD154-CD40 interactions can be used to prevent or even treat ongoing PLP139-151–induced relapsing EAE. However, little is known of the long-term effects of CD154 blockade on the development of antigen-specific T cell function. Here, we show that short-term treatment with anti-CD154 at the time of PLP139-151/CFA immunization inhibits clinical disease for up to 100 days after immunization. At this point, comparable numbers of Th1 cells are observed in anti-CD154 and control Ig–treated mice, as assessed by antigen-specific ELISPOT assays. Thus, the long-term Th1/Th2 balance is largely unaffected. Inflammatory responses are diminished in anti-CD154–treated mice, as indicated by reduced in vivo delayed-type hypersensitivity and reduced levels of splenic IFN-γ secretion in vitro. However, upon adoptive transfer of T cells isolated from the spleens of anti-CD154–treated mice, these cells contributed as effectively to clinical disease as those obtained from control-treated mice. Thus, anti-CD154 therapy leads to long-term therapeutic efficacy without exerting a long-term influence on Th1 development.

Authors

Laurence M. Howard, Serge Ostrovidov, Cassandra E. Smith, Mauro C. Dal Canto, Stephen D. Miller

×

Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1
Nobuo Kuramoto, … , John M. Robinson, Kiyofumi Yamanishi
Nobuo Kuramoto, … , John M. Robinson, Kiyofumi Yamanishi
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):243-250. https://doi.org/10.1172/JCI13563.
View: Text | PDF

Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1

  • Text
  • PDF
Abstract

Transglutaminase 1 (TGase 1) is one of the genes implicated in autosomal recessive congenital ichthyosis. Skin from TGase 1–/– mice, which die as neonates, lacks the normal insoluble cornified envelope and has impaired barrier function. Characterization of in situ dye permeability and transepidermal water loss revealed defects in the development of the skin permeability barrier in TGase 1–/– mice. In the stratum corneum of the skin, tongue, and forestomach, intercellular lipid lamellae were disorganized, and the corneocyte lipid envelope and cornified envelope were lacking. Neonatal TGase 1–/– mouse skin was taut and erythrodermic, but transplanted TGase 1–/– mouse skin resembled that seen in severe ichthyosis, with epidermal hyperplasia and marked hyperkeratosis. Abnormalities in those barrier structures remained, but transepidermal water loss was improved to control levels in the ichthyosiform skin. From these results, we conclude that TGase 1 is essential to the assembly and organization of the barrier structures in stratified squamous epithelia. We suggest that the ichthyosiform skin phenotype in TGase 1 deficiency develops the massive hyperkeratosis as a physical compensation for the defective cutaneous permeability barrier required for survival in a terrestrial environment.

Authors

Nobuo Kuramoto, Toshihiro Takizawa, Takami Takizawa, Masato Matsuki, Hiroyuki Morioka, John M. Robinson, Kiyofumi Yamanishi

×

A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation
Hans-Joachim Anders, … , Peter J. Nelson, Detlef Schlöndorff
Hans-Joachim Anders, … , Peter J. Nelson, Detlef Schlöndorff
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):251-259. https://doi.org/10.1172/JCI14040.
View: Text | PDF

A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation

  • Text
  • PDF
Abstract

The expression of chemokines and their receptors is thought to contribute to leukocyte infiltration and progressive renal fibrosis after unilateral ureter obstruction (UUO). We hypothesized that blocking the chemokine receptor CCR1 using the nonpeptide antagonist BX471 could reduce leukocyte infiltration and renal fibrosis after UUO. UUO kidneys from BX471-treated mice (day 0–10 and day 6–10) revealed a 40–60% reduction of interstitial macrophage and lymphocyte infiltrate compared with controls. Treated mice also showed a marked reduction of CCR1 and CCR5 mRNA levels, and FACS analysis showed a comparable reduction of CD8+/CCR5+ T cells. Markers of renal fibrosis, such as interstitial fibroblasts, interstitial volume, mRNA and protein expression for collagen I, were all significantly reduced by BX471-treatment compared with vehicle controls. By contrast treatment was ineffective when the drug was supplied only from days 0 to 5. In summary, blockade of CCR1 substantially reduces cell accumulation and renal fibrosis after UUO. Most interestingly, late onset of treatment is also effective. We therefore conclude that CCR1 blockade may represent a new therapeutic strategy for reducing cellular infiltration and renal fibrosis as major factors in the progression to end-stage renal failure.

Authors

Hans-Joachim Anders, Volker Vielhauer, Michael Frink, Yvonne Linde, Clemens D. Cohen, Simone M. Blattner, Matthias Kretzler, Frank Strutz, Matthias Mack, Hermann-Josef Gröne, James Onuffer, Richard Horuk, Peter J. Nelson, Detlef Schlöndorff

×

Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity
Arno Hänninen, … , William R. Heath, Leonard C. Harrison
Arno Hänninen, … , William R. Heath, Leonard C. Harrison
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):261-267. https://doi.org/10.1172/JCI13720.
View: Text | PDF

Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity

  • Text
  • PDF
Abstract

Antigen administration via oral and other mucosal routes can suppress systemic immunity to the antigen and has been used to prevent experimental autoimmune disease. This approach may prove ineffective or even harmful if it leads to a concomitant induction of cytotoxic T lymphocytes (CTLs), and indeed, mucosal administration of the model antigen ovalbumin (OVA) has been shown to elicit CTL activation while simultaneously inducing oral tolerance. Here we show that induction by oral OVA of CTLs in wild-type mice, and of diabetes in mice expressing OVA transgenically in pancreatic β cells, can be prevented by transiently blocking the CD40 ligand (CD40L). However, CD40L blockade did not diminish oral tolerance, as measured by suppression of systemic OVA-primed T cell proliferation, IFN-γ secretion, and Ab production. Consistent with these findings, mice lacking CD40 expression could be orally tolerized to OVA. Transient CD40L blockade therefore dissociates pathogenic from protective immunity and should enhance the efficacy and safety of oral tolerance for preventing autoimmune disease.

Authors

Arno Hänninen, Nathan R. Martinez, Gayle M. Davey, William R. Heath, Leonard C. Harrison

×

Regulation of lutropin circulatory half-life by the mannose/N-acetylgalactosamine-4-SO4 receptor is critical for implantation in vivo
Yiling Mi, … , Steven D. Shapiro, Jacques U. Baenziger
Yiling Mi, … , Steven D. Shapiro, Jacques U. Baenziger
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):269-276. https://doi.org/10.1172/JCI13997.
View: Text | PDF

Regulation of lutropin circulatory half-life by the mannose/N-acetylgalactosamine-4-SO4 receptor is critical for implantation in vivo

  • Text
  • PDF
Abstract

Lutropin (LH) directs ovulation and implantation by regulating the production of estrogen and progesterone. We have shown that the circulatory half-life of LH is controlled by the Man/GalNAc-4-SO4 receptor, which binds GalNAc-4-SO4 on LH oligosaccharides. The short half-life in conjunction with episodic release of LH from the pituitary accounts for the pulsatile rise and fall in circulating LH. Complete genetic ablation of the Man/GalNAc-4-SO4 receptor results in death in utero. Heterozygous female mice clear LH from the circulation more slowly and have smaller litters due to a reduction in the rate of implantation. This reduction is fully correctable by exogenous progesterone and estrogen, indicating that the rate of LH clearance is critical for the production of sufficient progesterone and estrogen for implantation. Thus, the Man/GalNAc-4-SO4 receptor regulates the endocrinological status of the female and is essential for an early event in embryonic development.

Authors

Yiling Mi, Steven D. Shapiro, Jacques U. Baenziger

×

Functional role of estrogen in pituitary tumor pathogenesis
Anthony P. Heaney, … , Manory Fernando, Shlomo Melmed
Anthony P. Heaney, … , Manory Fernando, Shlomo Melmed
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):277-283. https://doi.org/10.1172/JCI14264.
View: Text | PDF

Functional role of estrogen in pituitary tumor pathogenesis

  • Text
  • PDF
Abstract

Pituitary hyperplasia and lactotroph replication are induced by estrogen. The product of the pituitary tumor transforming gene (PTTG) exhibits in vitro and in vivo transforming activity and induces basic bFGF secretion, thereby modulating pituitary angiogenesis and tumor formation. We demonstrated previously that pituitary pttg is induced by estrogen and bFGF, the latter being expressed in a concordant fashion with pttg in experimental and human pituitary adenomas. We now elucidate the role of estrogen in paracrine regulation of pituitary tumorigenesis by PTTG. Coincident with the circulating rat estradiol surge and maximal pituitary proliferation, pituitary pttg mRNA, bFGF, and VEGF expression increased approximately threefold during proestrus and estrus. Osmotic mini-pump coinfusion of estrogen and antiestrogen abrogated estrogen-induced pituitary pttg expression in vivo, suppressed serum PRL concentrations by 88%, and attenuated prolactin-secreting pituitary tumor growth by 41% in rats. Antiestrogen treatment of primary human pituitary tumor cultures reduced PTTG expression approximately 65%. Pituitary pttg, bFGF, and VEGF are cyclically expressed during the rat estrus cycle, concordantly with estrogen levels. Because anti-estrogens reduced PTTG expression in human pituitary tumors in vitro and suppressed experimental tumor growth in vivo, concomitantly with reduced PRL secretion, these results indicate a role for selective antiestrogens in treating pituitary tumors.

Authors

Anthony P. Heaney, Manory Fernando, Shlomo Melmed

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts